<DOC>
	<DOCNO>NCT01195194</DOCNO>
	<brief_summary>The objective ass low pre-transplantation donor specific T-cell reactive patient measure Enzyme-linked immunosorbent spot ( ELISPOT ) assay safely manage Calcineurin inhibitor ( CNI ) -free Sirolimus ( SRL ) -based immunosuppression .</brief_summary>
	<brief_title>Selection Immunosuppression Kidney Transplant Recipients Depending Pre-transplant Donor-specific T-cell Reactivity .</brief_title>
	<detailed_description>Non randomize , pilot , prospective , open-label trial .</detailed_description>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>1 . Age donor recipient 18 65 year . 2 . Endstage renal disease schedule receive primary secondary renal allograft cadaveric , livingunrelated , livingrelated donor . Patients scheduled second transplant must maintain primary graft least 6 month transplantation , exception graft failure due technical reason . 3 . Panel reactive antibody ( PRA ) ≤ 20 % , negative standard crossmatch . 4 . Women childbearing potential must negative serum pregnancy test randomization . 5 . Women childbearing potential must agree use medically acceptable method contraception throughout treatment period 3 month follow discontinuation assign treatment . 6 . Signed date informed consent prior transplantation . 1 . Multiple organ transplant 2 . Recipients adult pediatric en bloc kidney transplant dual transplantation nonheart beat donor . 3 . Evidence active systemic localize major infection . 4 . Evidence infiltrate , cavitation , consolidation chest xray obtain screening/baseline evaluation . 5 . Use investigational drug treatment 4 week prior transplantation . 6 . Treatment voriconazole , ketoconazole , itraconazole , fluconazole , clotrimazole , astemizole , pimozide , terfenadine , erythromycin , clarithromycin , telithromycin , troleandomycin , rifampin , rifabutin , St. John 's Wort discontinue prior randomization . 7 . Treatment aminoglycosides , amphotericin B , cisplatin , cisapride , metoclopramide , cimetidine , bromocriptine , danazol , drug associate renal dysfunction discontinue prior randomization . 8 . Subjects screening/baseline total white blood cell count &lt; 2,000/mm3 absolute neutrophil count ( ANC ) &lt; 500 , platelet count &lt; 100,000/mm3 . 9 . Fasting triglyceride &gt; 400 mg/dL ( &gt; 4.6 mmol/L ) fast total cholesterol &gt; 300 mg/dL ( &gt; 7.8 mmol/L ) despite optimal lipidlowering therapy . 10 . History malignancy within 2 year enrollment ( except adequately treat basal cell squamous cell carcinoma skin ) . 11 . Autoimmune diseases inactive immunosuppressive treatment ( 3 month prior inclusion ) . 12 . Patient psychiatric disorder could noncompliance treatment . 13 . Non Caucasian patient . 14 . Active peptic ulcer could produce intestinal absorption disorder . 15 . Subjects know human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) positive . Patients hepatitis C virus ( HCV ) positive exclude polymerase chain reaction ( PCR ) positive transaminates value ≥2 upper normal value ( UNV ) . 16 . Diabetic patient . 17 . Body mass index high 30 Kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>T-cell lymphocyte allo-recognition</keyword>
	<keyword>CNI-free immunosuppressive regimen</keyword>
	<keyword>Enzyme-linked immunospot ( ELISPOT )</keyword>
</DOC>